Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

NCT07458529 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer, Adenocarcinoma
Neoadjuvant Therapy
Immunotherapy
Probio-M9
Tislelizumab
Randomized

Interventions

COMBINATION_PRODUCT: CRT+PD-1 inhibitor+Probio-M9
COMBINATION_PRODUCT: CRT+PD-1 inhibitor+placebo

Sponsor

Seventh Medical Center of PLA General Hospital